Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture

Obstetrics and Gynecology

Volumn 121, Issue 3, 2013, Pages 593-600

  Lanza, Lee L ^a   McQuay, Lisa J ^b   Rothman, Kenneth J ^b   Bone, Henry G ^b   Kaunitz, Andrew M ^b   Harel, Zeev ^b   Ataher, Quazi ^b   Ross, Douglas ^b   Arena, Philip L ^b   Wolter, Kevin D ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b not available

Author keywords

[No Author keywords available]

Indexed keywords

DEPOT MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANKLE FRACTURE; ARM FRACTURE; CLAVICLE FRACTURE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FINGER FRACTURE; FOLLOW UP; FOOT FRACTURE; FRACTURE; HAND FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; LEG FRACTURE; MAJOR CLINICAL STUDY; MULTIPLE TRAUMA; OUTCOME ASSESSMENT; PELVIS FRACTURE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIB FRACTURE; RISK ASSESSMENT; SHOULDER FRACTURE; SKULL FRACTURE; SPINE FRACTURE; WRIST FRACTURE;

EID: 84876222827     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318283d1a1     Document Type: Conference Paper

References (23)

1. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
2. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use. 4th Edition. Morb Mortal Wkly Rep MMWR 2010;59(RR-4):1-86.
3. Cromer BA, McArdle BJ, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996;129:671-6.
4. Westhoff C. Bone mineral density and DMPA. J Reprod Med 2002;47(Suppl 9):795-9.
5. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008;77:67-76.
6. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002;13:581-7.
7. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006;74:90-9.
8. Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2010;81:281-91.
9. Walker-Orr BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 1998;49:615-8.
10. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003;18:1947-54.
11. British National Formulary No.62. London (UK): BMJ Group and RPS Publishing; 2011.
12. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodríguez LA, Ruigómez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003;23: 686-9.
13. Van Staa TPA. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000:9:359-66.
14. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128-36.
15. Savitsky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 1964;36: 1627-39.
16. Van Staa TP, Dennison EM, Leufkens HGM, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001;29: 517-22.
17. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36.
18. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005;105: 1114-8.
19. Meier CR, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of DMPA and fracture risk. J Clin Endocrin Metab 2010;95: 4909-16.
20. Vestergaard P, Rejnmark L, Mosekilde L. The effects of DMPA and intrauterine device use on fracture risk in Danish women. Contraception 2008;78:459-64.
21. Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female army recruits. Osteoporos Int 2001;12:35-42.
22. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96.
23. Johnson CC, Burkman RT, Gold MA, Brown RT, Harel Z, Bruner A, et al. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health: study design, population characteristics and baseline bone mineral density. Contraception 2008;77:239-48.